180 Life Sciences [ATNF] vs Vericel [VCEL] Detailed Stock Comparison
180 Life Sciences
NASDAQ
Loading...
Vericel
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: 180 Life Sciences wins in 8 metrics, Vericel wins in 7 metrics, with 0 ties. 180 Life Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | 180 Life Sciences | Vericel | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.11 | 255.21 | 180 Life Sciences |
| Price-to-Book Ratio | 7.90 | 5.87 | Vericel |
| Debt-to-Equity Ratio | 26.25 | 32.74 | 180 Life Sciences |
| PEG Ratio | 0.00 | 74.44 | 180 Life Sciences |
| EV/EBITDA | -6.81 | 190.23 | 180 Life Sciences |
| Profit Margin (TTM) | 0.00% | 2.85% | Vericel |
| Operating Margin (TTM) | 0.00% | -3.21% | 180 Life Sciences |
| Return on Equity | -371.02% | 2.59% | Vericel |
| Return on Assets (TTM) | -55.46% | 0.18% | Vericel |
| Free Cash Flow (TTM) | $-1.48M | $-5.81M | 180 Life Sciences |
| 1-Year Return | 155.12% | -28.10% | 180 Life Sciences |
| Price-to-Sales Ratio (TTM) | N/A | 7.24 | N/A |
| Enterprise Value | $43.94M | $1.81B | Vericel |
| EV/Revenue Ratio | N/A | 7.26 | N/A |
| Gross Profit Margin (TTM) | N/A | 73.71% | N/A |
| Revenue per Share (TTM) | $0 | $5 | Vericel |
| Earnings per Share (Diluted) | $-14.95 | $0.14 | Vericel |
| Beta (Stock Volatility) | 0.41 | 1.27 | 180 Life Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
180 Life Sciences vs Vericel Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 180 Life Sciences | -8.03% | -36.79% | 71.17% | 358.10% | 284.80% | 179.65% |
| Vericel | 0.23% | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 180 Life Sciences | 155.12% | -98.40% | -99.87% | -99.86% | -99.86% | -99.86% |
| Vericel | -28.10% | 30.92% | 116.49% | 1,017.98% | 26.57% | -92.06% |
Performance & Financial Health Analysis: 180 Life Sciences vs Vericel
| Metric | ATNF | VCEL |
|---|---|---|
| Market Information | ||
| Market Cap | $1.08B | $1.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 37,591,630 | 456,322 |
| 90 Day Avg. Volume | 17,141,703 | 589,887 |
| Last Close | $4.81 | $35.44 |
| 52 Week Range | $0.66 - $17.75 | $33.09 - $63.00 |
| % from 52W High | -72.90% | -43.75% |
| All-Time High | $4,957.10 (Apr 12, 2021) | $1,590.00 (Sep 22, 1997) |
| % from All-Time High | -99.90% | -97.77% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.20% |
| Quarterly Earnings Growth | N/A | 0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.03% |
| Operating Margin (TTM) | 0.00% | -0.03% |
| Return on Equity (TTM) | -3.71% | 0.03% |
| Debt to Equity (MRQ) | 26.25 | 32.74 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.89 | $6.08 |
| Cash per Share (MRQ) | $0.37 | $2.32 |
| Operating Cash Flow (TTM) | $-3,159,107 | $47.24M |
| Levered Free Cash Flow (TTM) | $-3,003,669 | $-5,594,625 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: 180 Life Sciences vs Vericel
| Metric | ATNF | VCEL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.11 | 255.21 |
| Forward P/E | -15.30 | 74.44 |
| PEG Ratio | 0.00 | 74.44 |
| Price to Sales (TTM) | N/A | 7.24 |
| Price to Book (MRQ) | 7.90 | 5.87 |
| Market Capitalization | ||
| Market Capitalization | $1.08B | $1.80B |
| Enterprise Value | $43.94M | $1.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 7.26 |
| Enterprise to EBITDA | -6.81 | 190.23 |
| Risk & Other Metrics | ||
| Beta | 0.41 | 1.27 |
| Book Value per Share (MRQ) | $0.89 | $6.08 |
Financial Statements Comparison: 180 Life Sciences vs Vericel
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ATNF | VCEL |
|---|---|---|
| Revenue/Sales | $0 | $52.60M |
| Cost of Goods Sold | N/A | $16.33M |
| Gross Profit | N/A | $36.27M |
| Research & Development | $322,758 | $7.26M |
| Operating Income (EBIT) | $-1.73M | $-12.79M |
| EBITDA | $-1.72M | $-8.41M |
| Pre-Tax Income | $-1.73M | $-11.25M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-1.73M | $-11.25M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ATNF | VCEL |
|---|---|---|
| Cash & Equivalents | $3.72M | $73.49M |
| Total Current Assets | $4.03M | $197.64M |
| Total Current Liabilities | $3.94M | $39.45M |
| Long-Term Debt | $3,425 | $87.80M |
| Total Shareholders Equity | $7.71M | $295.49M |
| Retained Earnings | $-143.89M | $-404.06M |
| Property, Plant & Equipment | N/A | $68.72M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ATNF | VCEL |
|---|---|---|
| Operating Cash Flow | $-1.45M | $12.44M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $-853,723 | $-7.61M |
| Debt Repayment | $-3,320 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ATNF | VCEL |
|---|---|---|
| Shares Short | 1.14M | 5.56M |
| Short Ratio | 0.19 | 9.32 |
| Short % of Float | 0.47% | 0.14% |
| Average Daily Volume (10 Day) | 37,591,630 | 456,322 |
| Average Daily Volume (90 Day) | 17,141,703 | 589,887 |
| Shares Outstanding | 3.18M | 49.63M |
| Float Shares | 5.04M | 49.90M |
| % Held by Insiders | 0.10% | 0.01% |
| % Held by Institutions | 0.00% | 1.11% |
Dividend Analysis & Yield Comparison: 180 Life Sciences vs Vericel
| Metric | ATNF | VCEL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |